Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
A significant proportion of patients who survive coronavirus disease of 2019 (COVID-19) develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development of autoreactive IgG antibodies that cause...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2023-06-01
|
| Series: | Acta Materia Medica |
| Subjects: | |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2023-0004 |